Dasatinib for the Treatment of Moderate and Severe COVID-19
Status:
Not yet recruiting
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well dasatinib works in treating patients with moderate
and severe COVID-19. Dasatinib is a drug used to treat chronic leukemia which may help reduce
the strong inflammation caused by COVID-19 that can damage the lungs or other organs.